CoChat
Sign Up
Cited by 58Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal and yeast genetics research

Repositionable compounds with antifungal activity against multidrug resistant Candida auris identified in the medicines for malaria venture's pathogen box

Open access
Wall, Gina, Herrera, Natalia, Lopez-Ribot, José L.·2019·Journal of Fungi
DOI 10.3390/jof5040092PMC PMC6958377
Open this paper in CoChat — free accountOpen PDF

Abstract

Background. Candida auris has spread rapidly around the world as a causative agent of invasive candidiasis in health care facilities and there is an urgent need to find new options for treating this emerging, often multidrug-resistant pathogen. Methods. We screened the Pathogen Box® chemical library for inhibitors of C. auris strain 0390, both under planktonic and biofilm growing conditions. Results. The primary screen identified 12 compounds that inhibited at least 60% of biofilm formation or planktonic growth. After confirmatory dose-response assays, iodoquinol and miltefosine were selected as the two main leading repositionable compounds. Iodoquinol displayed potent in vitro inhibitory activity against planktonic C. auris but showed negligible inhibitory activity against biofilms; whereas miltefosine was able to inhibit the growth of C. auris under both planktonic and biofilm-growing conditions. Subsequent experiments confirmed their activity against nine other strains C. auris clinical isolates, irrespective of their susceptibility profiles against conventional antifungals. We extended our studies further to seven different species of Candida, also with similar findings. Conclusion. Both drugs possess broad spectrum of activity against Candida spp., including multiple strains of the emergent C. auris, and may constitute promising repositionable options for the development of novel therapeutics for the treatment of candidiasis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jof5040092

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clinical features of C. auris infections include biofilm persistence on abiotic surfaces and skin, immune evasion, and antifungal drug resistance.

    “The clinical features of these infections include biofilm persistence on abiotic surfaces and skin, immune evasion, and antifungal drug resistance (7–12).”

    From Dual function of <i>Candida auris</i> mannosyltransferase, MNT5, in biofilm community protection from antifungal therapy and the host (2025) · cites this paper as [10]

    The Introduction reports that C. auris persists on surfaces and skin, frequently resists antifungal drugs, and forms biofilms that defend against immune cells. It does not establish that the biofilms themselves persist on skin; the skin-persistence statement concerns C. auris generally. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 64

  1. [1]Banerjee S.N. Emori T.G. Culver D.H. Gaynes R.P. Jarvis W.R. Horan T. Edwards J.R. Tolson J. Henderson T. Martone W.J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989 Am. J. Med. 1991 91 S86 S89 10.1016/0002-9343(91)90349-3 1928197 · DOI · Paper page
  2. [2]Beck-Sague C. Jarvis W.R. National Nosocomial Infections Surveillance System Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990 J. Infect. Dis. 1993 167 1247 1251 10.1093/infdis/167.5.1247 8486965 · DOI
  3. [4]Fagan R.P. Edwards J.R. Park B.J. Fridkin S.K. Magill S.S. Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990–2010 Infect. Control Hosp. Epidemiol. 2013 34 893 899 10.1086/671724 23917902 PMC6452856 · DOI
  4. [5]Gudlaugsson O. Gillespie S. Lee K. Vande Berg J. Hu J. Messer S. Herwaldt L. Pfaller M. Diekema D. Attributable mortality of nosocomial candidemia, revisited Clin. Infect. Dis. 2003 37 1172 1177 10.1086/378745 14557960 · DOI · Paper page
  5. [6]Friedman D.Z.P. Schwartz I.S. Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens J. Fungi 2019 5 67 10.3390/jof5030067 PMC6787706 31330862 · DOI
  6. [7]Satoh K. Makimura K. Hasumi Y. Nishiyama Y. Uchida K. Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital Microbiol. Immunol. 2009 53 41 44 10.1111/j.1348-0421.2008.00083.x 19161556 · DOI · Paper page
  7. [8]Lee W.G. Shin J.H. Uh Y. Kang M.G. Kim S.H. Park K.H. Jang H.C. First three reported cases of nosocomial fungemia caused by Candida auris J. Clin. Microbiol. 2011 49 3139 3142 10.1128/JCM.00319-11 21715586 PMC3165631 · DOI
  8. [9]Chowdhary A. Voss A. Meis J.F. Multidrug-resistant Candida auris: ‘New kid on the block’ in hospital-associated infections? J. Hosp. Infect. 2016 94 209 212 10.1016/j.jhin.2016.08.004 27634564 · DOI · Paper page
  9. [11]Al-Siyabi T. Al Busaidi I. Balkhair A. Al-Muharrmi Z. Al-Salti M. Al’Adawi B. First report of Candida auris in Oman: Clinical and microbiological description of five candidemia cases J. Infect. 2017 75 373 376 10.1016/j.jinf.2017.05.016 28579303 · DOI
  10. [12]Arauz A.B. Caceres D.H. Santiago E. Armstrong P. Arosemena S. Ramos C. Espinosa-Bode A. Borace J. Hayer L. Cedeno I. Isolation of Candida auris from 9 patients in Central America: Importance of accurate diagnosis and susceptibility testing Mycoses 2017 10.1111/myc.12709 28945325 · DOI
  11. [13]Lockhart S.R. Etienne K.A. Vallabhaneni S. Farooqi J. Chowdhary A. Govender N.P. Colombo A.L. Calvo B. Cuomo C.A. Desjardins C.A. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses Clin. Infect. Dis. 2017 64 134 140 10.1093/cid/ciw691 27988485 PMC5215215 · DOI · Paper page
  12. [14]Vallabhaneni S. Kallen A. Tsay S. Chow N. Welsh R. Kerins J. Kemble S.K. Pacilli M. Black S.R. Landon E. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus—United States, May 2013-August 2016 MMWR Morb. Mortal. Wkly. Rep. 2016 65 1234 1237 10.15585/mmwr.mm6544e1 27832049 · DOI · Paper page
  13. [15]Oh B.J. Shin J.H. Kim M.N. Sung H. Lee K. Joo M.Y. Shin M.G. Suh S.P. Ryang D.W. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea Med. Mycol. 2011 49 98 102 10.3109/13693786.2010.493563 20560864 · DOI
  14. [16]De Jong A.W. Hagen F. Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments Mycopathologia 2019 184 353 365 10.1007/s11046-019-00351-w 31209693 · DOI
  15. [17]Schelenz S. Hagen F. Rhodes J.L. Abdolrasouli A. Chowdhary A. Hall A. Ryan L. Shackleton J. Trimlett R. Meis J.F. First hospital outbreak of the globally emerging Candida auris in a European hospital Antimicrob. Resist. Infect. Control 2016 5 35 10.1186/s13756-016-0132-5 27777756 PMC5069812 · DOI · Paper page
  16. [18]Piedrahita C.T. Cadnum J.L. Jencson A.L. Shaikh A.A. Ghannoum M.A. Donskey C.J. Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species Infect. Control Hosp. Epidemiol. 2017 38 1107 1109 10.1017/ice.2017.127 28693657 · DOI
  17. [20]Kean R. Sherry L. Townsend E. McKloud E. Short B. Akinbobola A. Mackay W.G. Williams C. Jones B.L. Ramage G. Surface disinfection challenges for Candida auris: An in-vitro study J. Hosp. Infect. 2018 98 433 436 10.1016/j.jhin.2017.11.015 29203448 · DOI
  18. [21]Short B. Brown J. Delaney C. Sherry L. Williams C. Ramage G. Kean R. Candida auris exhibits resilient biofilm characteristics in vitro: Implications for environmental persistence J. Hosp. Infect. 2019 10.1016/j.jhin.2019.06.006 31226270 · DOI · Paper page
  19. [22]Ledwoch K. Maillard J.Y. Candida auris Dry Surface Biofilm (DSB) for Disinfectant Efficacy Testing Materials 2018 12 18 10.3390/ma12010018 30577589 PMC6337396 · DOI
  20. [23]Rutala W.A. Kanamori H. Gergen M.F. Sickbert-Bennett E.E. Weber D.J. Susceptibility of Candida auris and Candida albicans to 21 germicides used in healthcare facilities Infect. Control Hosp. Epidemiol. 2019 40 380 382 10.1017/ice.2019.1 30767810 · DOI
  21. [26]Sarma S. Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris Infect. Drug Resist. 2017 10 155 165 10.2147/IDR.S116229 28652784 PMC5476417 · DOI
  22. [27]Walia K. Chowdhary A. Ohri V.C. Chakrabarti A. Multidrug-resistant Candida auris: Need for alert among microbiologists Indian J. Med. Microbiol. 2017 35 436 10.4103/ijmm.IJMM_17_345 29063895 · DOI
  23. [29]Lockhart S.R. Candida auris and multidrug resistance: Defining the new normal Fungal Genet Biol 2019 131 103243 10.1016/j.fgb.2019.103243 31228646 PMC12012538 · DOI · Paper page
  24. [30]Clancy C.J. Nguyen M.H. Emergence of Candida auris: An International Call to Arms Clin. Infect. Dis. 2017 64 141 143 10.1093/cid/ciw696 27989986 · DOI
  25. [31]Sherry L. Ramage G. Kean R. Borman A. Johnson E.M. Richardson M.D. Rautemaa-Richardson R. Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris Emerg. Infect. Dis. 2017 23 328 331 10.3201/eid2302.161320 28098553 PMC5324806 · DOI · Paper page
  26. [32]Kean R. Delaney C. Rajendran R. Sherry L. Metcalfe R. Thomas R. McLean W. Williams C. Ramage G. Gaining insights from candida biofilm heterogeneity: One size does not fit all J. Fungi 2018 4 12 10.3390/jof4010012 29371505 PMC5872315 · DOI
  27. [33]Kean R. Ramage G. Combined Antifungal Resistance and Biofilm Tolerance: The Global Threat of Candida auris mSphere 2019 4 e00458-19 10.1128/mSphere.00458-19 31366705 PMC6669339 · DOI
  28. [34]Butts A. Krysan D.J. Antifungal drug discovery: Something old and something new PLoS Pathog. 2012 8 e1002870 10.1371/journal.ppat.1002870 22969422 PMC3435257 · DOI
  29. [35]Nosengo N. New tricks for old drugs Nature 2016 534 314 316 10.1038/534314a 27306171 · DOI
  30. [36]Ashburn T.T. Thor K.B. Drug repositioning: Identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 2004 3 673 683 10.1038/nrd1468 15286734 · DOI · Paper page
  31. [37]Kaul G. Shukla M. Dasgupta A. Chopra S. Update on drug-repurposing: Is it useful for tackling antimicrobial resistance? Future Microbiol. 2019 14 829 831 10.2217/fmb-2019-0122 31368794 · DOI
  32. [38]Veale C.G.L. Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease ChemMedChem 2019 14 386 453 10.1002/cmdc.201800755 30614200 · DOI
  33. [41]Pierce C.G. Uppuluri P. Tristan A.R. Wormley F.L. Jr. Mowat E. Ramage G. Lopez-Ribot J.L. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing Nat. Protoc. 2008 3 1494 1500 10.1038/nprot.2008.141 18772877 PMC2741160 · DOI · Paper page
  34. [42]Pierce C.G. Uppuluri P. Tummala S. Lopez-Ribot J.L. A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms JoVE J. Vis. Exp. 2010 44 e2287 10.3791/2287 PMC3185615 21048668 · DOI
  35. [43]Ramage G. Vandewalle K. Wickes B.L. Lopez-Ribot J.L. Characteristics of biofilm formation by Candida albicans Rev. Iberoam. Micol. 2001 18 163 170 15496122
  36. [44]Wiederhold N.P. Antifungal resistance: Current trends and future strategies to combat Infect. Drug Resist. 2017 10 249 259 10.2147/IDR.S124918 28919789 PMC5587015 · DOI
  37. [46]Vila T. Lopez-Ribot J.L. Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors Antimicrob. Agents Chemother. 2017 61 10.1128/AAC.02006-16 27795383 PMC5192139 · DOI
  38. [48]Verweij J. Planting A. van der Burg M. Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours J. Cancer Res. Clin. Oncol. 1992 118 606 608 10.1007/BF01211805 1325463 PMC12201078 · DOI
  39. [49]Verweij J. Gandia D. Planting A.S. Stoter G. Armand J.P. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer Eur. J. Cancer 1993 29 778 779 10.1016/S0959-8049(05)80369-7 8471342 · DOI
  40. [50]Planting A.S. Stoter G. Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer Eur. J. Cancer 1993 29 518 519 10.1016/S0959-8049(05)80142-X 8435202 · DOI
  41. [51]Smorenburg C.H. Seynaeve C. Bontenbal M. Planting A.S. Sindermann H. Verweij J. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients Anti-Cancer Drugs 2000 11 825 828 10.1097/00001813-200011000-00006 11142690 · DOI
  42. [52]Sundar S. Rosenkaimer F. Makharia M.K. Goyal A.K. Mandal A.K. Voss A. Hilgard P. Murray H.W. Trial of oral miltefosine for visceral leishmaniasis Lancet 1998 352 1821 1823 10.1016/S0140-6736(98)04367-0 9851383 · DOI
  43. [53]Jha T.K. Sundar S. Thakur C.P. Bachmann P. Karbwang J. Fischer C. Berman J. Voss A. Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis N. Engl. J. Med. 1999 341 1795 1800 10.1056/NEJM199912093412403 10588964 · DOI
  44. [54]Soto J. Toledo J. Gutierrez P. Nicholls R.S. Padilla J. Engel J. Berman J. Fischer C. Voss A. Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral Agent Clin. Infect. Dis. 2001 33 57 61 10.1086/322689 11528586 · DOI
  45. [55]Sundar S. Jha T.K. Thakur C.P. Engel J. Sindermann H. Fischer C. Berman J. Junge K. Bryceson A. Oral Miltefosine for Indian Visceral Leishmaniasis N. Engl. J. Med. 2002 347 1739 1746 10.1056/NEJMoa021556 12456849 · DOI
  46. [56]Bhattacharya S.K. Jha T.K. Sundar S. Thakur C.P. Engel J. Sindermann H. Berman J.D. Junge K. Karbwang J. Bryceson A.D.M. Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India Clin. Infect. Dis. 2004 38 217 221 10.1086/380638 14699453 · DOI
  47. [57]Soto J. Arana B.A. Toledo J. Rizzo N. Vega J.C. Diaz A. Junge K. Luz P. Gutierrez M. Junge J.E. Miltefosine for New World Cutaneous Leishmaniasis Clin. Infect. Dis. 2004 38 1266 1272 10.1086/383321 15127339 · DOI
  48. [58]Soto J. Toledo J. Valda L. Balderrama M. Rea I. Parra R. Fuentelsaz C. Ardiles J. Soto P. Molleda F. Treatment of Bolivian Mucosal Leishmaniasis with Miltefosine Clin. Infect. Dis. 2007 44 350 356 10.1086/510588 17205440 · DOI
  49. [59]Bhattacharya S.K. Sinha P.K. Sundar S. Thakur C.P. Jha T.K. Pandey K. Das V.R. Kumar N. Lal C. Verma N. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis J. Infect. Dis. 2007 196 591 598 10.1086/519690 17624846 · DOI
  50. [60]Dorlo T.P. Balasegaram M. Beijnen J.H. de Vries P.J. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis J. Antimicrob. Chemother. 2012 67 2576 2597 10.1093/jac/dks275 22833634 · DOI
  51. [62]Linam W.M. Ahmed M. Cope J.R. Chu C. Visvesvara G.S. da Silva A.J. Qvarnstrom Y. Green J. Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis Pediatrics 2015 135 e744 e748 10.1542/peds.2014-2292 25667249 PMC4634363 · DOI
  52. [63]Vila T.V. Chaturvedi A.K. Rozental S. Lopez-Ribot J.L. In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis Antimicrob. Agents Chemother. 2015 59 7611 7620 10.1128/AAC.01890-15 26416861 PMC4649157 · DOI
  53. [64]Compain F. Botterel F. Sitterle E. Paugam A. Bougnoux M.E. Dannaoui E. In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp. J. Med. Microbiol. 2015 64 309 311 10.1099/jmm.0.000019 25596124 · DOI
  54. [65]Rossi D.C.P. Spadari C.C. Nosanchuk J.D. Taborda C.P. Ishida K. Miltefosine is fungicidal to Paracoccidioides spp. yeast cells but subinhibitory concentrations induce melanisation Int. J. Antimicrob. Agents 2017 49 465 471 10.1016/j.ijantimicag.2016.12.020 28279786 · DOI
  55. [66]Quaesaet L. Stindel E. Lanternier F. Williams T. Jaffuel S. Moalic E. Garcia Hermoso D. Lortholary O. Ansart S. Miltefosine-based regimen as salvage therapy in Lomentospora prolificans bone and joint infection Med. Mal. Infect. 2018 48 63 65 10.1016/j.medmal.2017.10.005 29153288 · DOI
  56. [67]Spadari C.C. Vila T. Rozental S. Ishida K. Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts Antimicrob. Agents Chemother. 2018 62 10.1128/AAC.00312-18 PMC6105859 29844051 · DOI
  57. [68]Spadari C.C. de Bastiani F. Lopes L.B. Ishida K. Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis Int. J. Nanomed. 2019 14 5187 5199 10.2147/IJN.S205350 31371955 PMC6636311 · DOI
  58. [69]Kuhlmann F.M. Fleckenstein J.M. Antiparasitic Agents Infectious Diseases Elsevier Amsterdam, The Netherlands 2017 1345 1372 10.1016/b978-0-7020-6285-8.00157-x · DOI
  59. [70]American Association of Pediatrics Committee on Drugs Clioquinol (Iodochlorhydroxyquin, Vioform) and Iodoquinol (Diiodohydroxyquin): Blindness and Neuropathy Peadiatrics 1990 86 797 798 2146587
  60. [71]Burnett B.P. Mitchell C.M. Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole Cutis 2008 82 273 280 19055171
  61. [72]Lawung R. Cherdtrakulkiat R. Nabu S. Prachayasittikul S. Isarankura-Na-Ayudhya C. Prachayasittikul V. Repositioning of 8-hydroxyquinoline derivatives as a new promising candidate for combating multidrug resistant Neisseria gonorrhoeae EXCLI J. 2018 17 840 846 10.17179/excli2018-1602 30233282 PMC6141828 · DOI
  62. [73]Wall G. Chaturvedi A.K. Wormley F.L. Wiederhold N.P. Patterson H.P. Patterson T.F. Lopez-Ribot J.L. Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development Antimicrob. Agents Chemother. 2018 62 10.1128/AAC.01084-18 PMC6153848 30104269 · DOI
  63. [74]De Oliveira H.C. Monteiro M.C. Rossi S.A. Peman J. Ruiz-Gaitan A. Mendes-Giannini M.J.S. Mellado E. Zaragoza O. Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris Front. Cell. Infect. Microbiol. 2019 9 83 10.3389/fcimb.2019.00083 31001487 PMC6454888 · DOI
  64. [75]Dorlo T.P. van Thiel P.P. Huitema A.D. Keizer R.J. de Vries H.J. Beijnen J.H. de Vries P.J. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients Antimicrob. Agents Chemother. 2008 52 2855 2860 10.1128/AAC.00014-08 18519729 PMC2493105 · DOI

Cited by

Sorted by citations

Authors
Wall, G., Herrera, N., & Lopez-Ribot, J. L.
Affiliations
  • The University of Texas at San Antonio (US)
  • Department of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA
ORCID
Venue
Journal of Fungi
Publisher
MDPI AG
Published
2019-10-01
Volume
5
Issue
4
Pages
92
ISSN
2309-608X (ISSN-L)
DOI
10.3390/jof5040092
PMC
PMC6958377
OpenAlex
W2979054781
Cited by
58
References
7
Citations by year
2026: 1 · 2025: 6 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 10 · 2020: 14 · 2019: 1
FWCI
6.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Fungi (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Allergy and Infectious Diseases (R21AI140823)
  • U.S. Department of Defense (Science, Mathematics, and Research for Transformation (SMART) fellowship)
  • Margaret Batts Tobin Foundation (No number)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
Candida auris, multidrug resistance, antifungal drug repurposing, iodoquinol, miltefosine, biofilm inhibition, planktonic growth inhibition, invasive candidiasis, Candida species, antifungal activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review